Zydus Launches World’s First Nivolumab Biosimilar ‘Tishtha™’ in India at One-Fourth the Cost

Zydus Lifesciences Limited has launched Tishtha™, the world’s first biosimilar of Nivolumab, in India. The launch marks a major step in expanding access to advanced cancer treatment through affordable immunotherapy.

Tishtha™ is used to treat multiple types of cancer and strengthens Zydus’ presence in biologics and immuno-oncology.

Pricing and Dosage Details

Tishtha™ will be available in two strengths:

• 100 mg at ₹28,950
• 40 mg at ₹13,950

These prices are nearly one-fourth of the reference drug, significantly reducing the cost burden for patients. The two-dose option allows doctors to optimise treatment and reduce medicine wastage, which is crucial in cancer care.

Expected Patient Impact

The launch of Tishtha™ is expected to benefit over 5 lakh cancer patients in India. By improving affordability and ensuring consistent availability, the treatment helps patients continue therapy without interruptions, reducing both medical and financial stress.

Management Commentary

Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Ltd., said the company aims to make advanced cancer care accessible to every patient. He added that Tishtha™ reflects Zydus’ commitment to patient-centric, high-quality biosimilar therapies and long-term support throughout the treatment journey.

Focus on Access, Consistency and Reach

Zydus highlighted that effective cancer care depends on affordability, reliable supply, and wide reach. Manufactured in India, Tishtha™ ensures dependable availability of checkpoint inhibitor therapy across multiple treatment cycles, which is essential for cancer patients.

About Zydus Lifesciences

Zydus Lifesciences Limited is an innovation-driven healthcare company with a strong presence in pharmaceuticals, consumer wellness, and MedTech. As of September 30, 2025, the group employs 29,000 people globally, including 1,500 R&D scientists, and operates across India, the US, and other global markets.

Also Read: Best Long-Term Stocks in Jan 2026 – 5yr CAGR Basis!

Zydus Lifesciences Share Price Movement

Zydus Lifesciences share price (NSE: ZYDUSLIFE) was trading at ₹884 on the NSE at 11:47 am on January 22, up ₹7.75 or 0.88% for the day. The stock opened at ₹876.25 and moved between an intraday low of ₹875.80 and a high of ₹888.00. Zydus Lifesciences has a 52-week high of ₹1,059.05 and a 52-week low of ₹795, while offering a dividend yield of 1.24%, translating to a quarterly dividend of ₹2.74 per share.

Conclusion

With the launch of Tishtha™, Zydus has taken a major step in making advanced cancer immunotherapy more affordable and accessible in India. The biosimilar not only lowers treatment costs but also ensures consistent care, offering new hope to lakhs of cancer patients across the country.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.